U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C19H21N3O.C4H6O6
Molecular Weight 764.8659
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOLPIDEM TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C3=CC=C(C)C=C3.CN(C)C(=O)CC4=C(N=C5C=CC(C)=CN45)C6=CC=C(C)C=C6

InChI

InChIKey=VXRDAMSNTXUHFX-CEAXSRTFSA-N
InChI=1S/2C19H21N3O.C4H6O6/c2*1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19;5-1(3(7)8)2(6)4(9)10/h2*5-10,12H,11H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C19H21N3O
Molecular Weight 307.3895
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Zolpidem interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem in vitro binds the BZ1 receptor preferentially with a high affinity ratio of the α1/α5 subunits. This selective binding of zolpidem on the BZ1 receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep in human studies of zolpidem tartrate at hypnotic doses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMBIEN

Approved Use

Ambien (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Ambien has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14)

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
121 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
59 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
26 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.5%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.5%
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
n = 65
Health Status: unhealthy
Condition: sleep disturbances
Age Group: 2 - 12 years
Sex: M+F
Population Size: 65
Sources:
Other AEs: Psychiatric symptom, Gastrointestinal disorder (NOS)...
Other AEs:
Psychiatric symptom (6 patients)
Gastrointestinal disorder (NOS) (6 patients)
Nervous system disorder NOS (5 patients)
Sources:
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
unhealthy, 68 years
n = 1
Health Status: unhealthy
Condition: sleep disturbances
Age Group: 68 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Disc. AE: Drowsiness, Vertigo...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1.1%)
Vertigo (0.8%)
Amnesia (0.5%)
Nausea (0.5%)
Headache (0.4%)
Fall (0.4%)
Sources:
90 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
n = 1701
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1701
Sources:
Disc. AE: Drowsiness, Dizziness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (0.5%)
Dizziness (0.4%)
Headache (0.5%)
Nausea (0.6%)
Vomiting (0.5%)
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
n = 344
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 344
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 10 patients)
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
n = 54
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 54
Sources:
Disc. AE: Somnolence, Coma...
AEs leading to
discontinuation/dose reduction:
Somnolence (100%)
Coma (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nervous system disorder NOS 5 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
n = 65
Health Status: unhealthy
Condition: sleep disturbances
Age Group: 2 - 12 years
Sex: M+F
Population Size: 65
Sources:
Gastrointestinal disorder (NOS) 6 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
n = 65
Health Status: unhealthy
Condition: sleep disturbances
Age Group: 2 - 12 years
Sex: M+F
Population Size: 65
Sources:
Psychiatric symptom 6 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
n = 65
Health Status: unhealthy
Condition: sleep disturbances
Age Group: 2 - 12 years
Sex: M+F
Population Size: 65
Sources:
Death grade 5, 1 patient
Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
unhealthy, 68 years
n = 1
Health Status: unhealthy
Condition: sleep disturbances
Age Group: 68 years
Sex: F
Population Size: 1
Sources:
Fall 0.4%
Disc. AE
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Headache 0.4%
Disc. AE
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Amnesia 0.5%
Disc. AE
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Nausea 0.5%
Disc. AE
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Vertigo 0.8%
Disc. AE
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Drowsiness 1.1%
Disc. AE
50 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 1959
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1959
Sources:
Dizziness 0.4%
Disc. AE
90 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
n = 1701
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1701
Sources:
Drowsiness 0.5%
Disc. AE
90 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
n = 1701
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1701
Sources:
Headache 0.5%
Disc. AE
90 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
n = 1701
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1701
Sources:
Vomiting 0.5%
Disc. AE
90 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
n = 1701
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1701
Sources:
Nausea 0.6%
Disc. AE
90 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
n = 1701
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 1701
Sources:
Death grade 5, 10 patients
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
n = 344
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 344
Sources:
Coma 1 patient
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
n = 54
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 54
Sources:
Somnolence 100%
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
n = 54
Health Status: unhealthy
Condition: sleep disturbances
Age Group: adult
Sex: unknown
Population Size: 54
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: A single-dose interaction study with zolpidem tartrate 10 mg and rifampin (CYP3A4 inducer) 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), Cmax (-58%), and T1/2 (-36 %) of zolpidem together
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.
1999 Jul
Extraordinary arousal from semi-comatose state on zolpidem. A case report.
2000 Jan
Mice lacking the long splice variant of the gamma 2 subunit of the GABA(A) receptor are more sensitive to benzodiazepines.
2000 Jun
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
[Correction of sleep disorders and efficacy of antihypertensive monotherapy in elderly patients: use of ivadal].
2001
[Zolpidem (ivadal) treatment of sleep disorders].
2001
Measurement of cerebral perfusion after zolpidem administration in the baboon model.
2001
Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment.
2001
Melatonin for preventing and treating jet lag.
2001
The acute effects of zolpidem compared to diazepam and lorazepam using radiotelemetry.
2001 Apr
Zolpidem for antipsychotic-induced parkinsonism.
2001 Apr
Alternative medicine. Achieving balance between herbal remedies and medical therapy.
2001 Aug
Zolpidem abuse.
2001 Aug
Diminished allopregnanolone enhancement of GABA(A) receptor currents in a rat model of chronic temporal lobe epilepsy.
2001 Dec 1
Functional analysis of GABA(A) receptors in nucleus tractus solitarius neurons from neonatal rats.
2001 Dec 7
[Benzodiazepines and benzodiazepine receptor agonists in the treatment of sleep disorders--importance and dangers. Evaluation from the clinical medical view].
2001 Jan
Acute zolpidem overdose leading to coma and respiratory failure.
2001 Jul
[Homeopathic specialties as substitutes for benzodiazepines: double-blind vs. placebo study].
2001 Jul-Aug
A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
2001 Jun
gamma-Aminobutyric acid(A) receptor subunit expression predicts functional changes in hippocampal dentate granule cells during postnatal development.
2001 Jun
[3H]Ro 15-1788 binding sites to brain membrane of the saltwater Mugil cephalus.
2001 Mar
Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux.
2001 May
A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia.
2001 May-Jun
Treatment of insomnia in hospitalized patients.
2001 Nov
Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation.
2001 Nov
Arousal from a semi-comatose state on zolpidem.
2001 Oct
Prevalence between different alpha subunits performing the benzodiazepine binding sites in native heterologous GABA(A) receptors containing the alpha2 subunit.
2001 Oct
Insomnia: therapeutic approach.
2001 Sep
Zolpidem in restless legs syndrome.
2002
Tolerability of hypnosedatives in older patients.
2002
Melatonin for the prevention and treatment of jet lag.
2002
Hallucinations and Zolpidem.
2002 Aug
The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem.
2002 Aug 15
Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors.
2002 Feb 15
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography.
2002 Jul
[Abuse, tolerance and dependence of zolpidem: three case reports].
2002 Jul-Aug
"As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting.
2002 Mar
Soyka M, Bottlender R, Möller H-J; Epidemiological evidence for a low abuse potential of zolpidem; Pharmacopsychiatry 2000, 33: 138 - 141.
2002 Mar
Zolpidem in progressive supranuclear palsy.
2002 Mar
Sleep disorders and daytime sleepiness in state police shiftworkers.
2002 Mar-Apr
Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.
2002 May
Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells.
2002 May
Adaptive time-frequency parametrization in pharmaco EEG.
2002 May 30
Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions.
2002 May 8
Functional characterization of GABA(A) receptors in neonatal hypothalamic brain slice.
2002 Oct
Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use.
2002 Oct
GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem.
2002 Sep
Mechanisms of anabolic androgenic steroid modulation of alpha(1)beta(3)gamma(2L) GABA(A) receptors.
2002 Sep
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes.
2002 Sep 13
Patents

Patents

Sample Use Guides

Dosage in Adults: the recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness. The total dose of AMBIEN (zolpidem tartrate) should not exceed 10 mg once daily immediately before bedtime. Ambien should be taken as a single dose and should not be readministered during the same night.
Route of Administration: Oral
Human embryonic kidney (HEK) 293 cells stably expressing recombinant α1β2γ2s GABA(A) receptors were exposed to zolpidem (1 and 10 μmol/L) for short-term (2 h daily for 1, 2, or 3 consecutive days) or long-term (continuously for 48 h). Radioligand binding studies were used to determine the parameters of [(3)H]flunitrazepam binding sites. A single (2 h) or repeated (2 h daily for 2 or 3 d) short-term exposure to zolpidem affected neither the maximum number of [(3)H]flunitrazepam binding sites nor the affinity. In both control and short-term zolpidem treated groups, addition of GABA (1 nmol/L-1 mmol/L) enhanced [(3)H]flunitrazepam binding in a concentration-dependent manner. The maximum enhancement of [(3)H]flunitrazepam binding in short-term zolpidem treated group was not significantly different from that in the control group. In contrast, long-term exposure to zolpidem resulted in significantly increase in the maximum number of [(3)H]flunitrazepam binding sites without changing the affinity. Furthermore, long-term exposure to zolpidem significantly decreased the ability of GABA to stimulate [(3)H]flunitrazepam binding.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:11:16 GMT 2023
Edited
by admin
on Fri Dec 15 15:11:16 GMT 2023
Record UNII
WY6W63843K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOLPIDEM TARTRATE
EP   HSDB   JAN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
(2R,3R)-2,3-DIHYDROXYSUCCINIC ACID - N,N-DIMETHYL-2-(6-METHYL-2-(4-METHYLPHENYL)IMIDAZO(1,2-A)PYRIDIN-3-YL)ACETAMIDE (1:2)
Common Name English
AMBIEN
Brand Name English
STILNOX
Brand Name English
ZOLPIDEM TARTRATE [MART.]
Common Name English
SL-80.0750
Code English
N,N,6-TRIMETHYL-2-P-TOLYL-IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE L-(+)-HEMITARTRATE (2:1)
Common Name English
Zolpidem tartrate [WHO-DD]
Common Name English
ZOLPIDEM TARTRATE CIV
USP-RS  
Common Name English
ZOLPIDEM HEMITARTRATE
Common Name English
N,N,6-TRIMETHYL-2-P-TOLYLIMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE L-(+)-TARTRATE (2:1)
Common Name English
ZOLPIDEM L-(+)-HEMITARTRATE [MI]
Common Name English
MYSLEE
Brand Name English
ZOLPIDEM TARTRATE [ORANGE BOOK]
Common Name English
INTERMEZZO
Brand Name English
IVADAL
Brand Name English
ZOLPIDEM TARTRATE [EP MONOGRAPH]
Common Name English
NIOTAL
Brand Name English
ZOLPIDEM TARTRATE [USP MONOGRAPH]
Common Name English
ZOLPIDEM TARTRATE [JAN]
Common Name English
ZOLPIDEM TARTRATE [USAN]
Common Name English
SL-80.0750-23N
Code English
SL 80.0750-23N
Code English
ZOLPIDEM TARTRATE [HSDB]
Common Name English
STILNOCT
Brand Name English
ZOLPIDEM TARTRATE CIV [USP-RS]
Common Name English
TOVALT
Brand Name English
IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE, N,N,6-TRIMETHYL-2-(4-METHYLPHENYL)-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (2:1)
Common Name English
ZOLPIDEM L-(+)-HEMITARTRATE
MI  
Common Name English
ZOLPIDEM TARTRATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29756
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
Code System Code Type Description
RXCUI
221183
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY RxNorm
DAILYMED
WY6W63843K
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
HSDB
7045
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
RS_ITEM_NUM
1724907
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
EVMPD
SUB05192MIG
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
ChEMBL
CHEMBL911
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
USAN
Y-28
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
MERCK INDEX
m11661
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY Merck Index
EVMPD
SUB127297
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
NCI_THESAURUS
C29553
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
FDA UNII
WY6W63843K
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
SMS_ID
100000091037
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
DRUG BANK
DBSALT001047
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
CHEBI
10126
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
PUBCHEM
441338
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID00912795
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
CAS
99294-93-6
Created by admin on Fri Dec 15 15:11:16 GMT 2023 , Edited by admin on Fri Dec 15 15:11:16 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY